Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumors.
Flippot R, Teixeira M, Rey-Cardenas M, Carril-Ajuria L, Rainho L, Naoun N, Jouniaux JM, Boselli L, Naigeon M, Danlos FX, Escudier B, Scoazec JY, Cassard L, Albiges L, Chaput N. Flippot R, et al. Among authors: naigeon m. J Immunother Cancer. 2024 Apr 16;12(4):e008636. doi: 10.1136/jitc-2023-008636. J Immunother Cancer. 2024. PMID: 38631710 Free PMC article. Review.
Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study.
Mourey L, Rainho LT, Dalban C, Carril-Ajuria L, Negrier S, Chevreau C, Gravis G, Thibault C, Laguerre B, Barthelemy P, Borchiellini D, Gross-Goupil M, Geoffrois L, Rolland F, Thiery-Vuillemin A, Tantot F, Chaput N, Naigeon M, Teixeira M, Escudier B, Flippot R, Albiges L. Mourey L, et al. Among authors: naigeon m. Eur J Cancer. 2024 Apr;201:113589. doi: 10.1016/j.ejca.2024.113589. Epub 2024 Feb 3. Eur J Cancer. 2024. PMID: 38382153
Human virome profiling identified CMV as the major viral driver of a high accumulation of senescent CD8+ T cells in patients with advanced NSCLC.
Naigeon M, Roulleaux Dugage M, Danlos FX, Boselli L, Jouniaux JM, de Oliveira C, Ferrara R, Duchemann B, Berthot C, Girard L, Flippot R, Albiges L, Farhane S, Saulnier P, Lacroix L, Griscelli F, Roman G, Hulett T, Marabelle A, Cassard L, Besse B, Chaput N. Naigeon M, et al. Sci Adv. 2023 Nov 10;9(45):eadh0708. doi: 10.1126/sciadv.adh0708. Epub 2023 Nov 8. Sci Adv. 2023. PMID: 37939189 Free PMC article.
The purinergic receptor P2X7 and the NLRP3 inflammasome are druggable host factors required for SARS-CoV-2 infection.
Lécuyer D, Nardacci R, Tannous D, Gutierrez-Mateyron E, Deva Nathan A, Subra F, Di Primio C, Quaranta P, Petit V, Richetta C, Mostefa-Kara A, Del Nonno F, Falasca L, Marlin R, Maisonnasse P, Delahousse J, Pascaud J, Deprez E, Naigeon M, Chaput N, Paci A, Saada V, Ghez D, Mariette X, Costa M, Pistello M, Allouch A, Delelis O, Piacentini M, Le Grand R, Perfettini JL. Lécuyer D, et al. Among authors: naigeon m. Front Immunol. 2023 Oct 18;14:1270081. doi: 10.3389/fimmu.2023.1270081. eCollection 2023. Front Immunol. 2023. PMID: 37920468 Free PMC article.
Immunosenescence, inflammaging, and cancer immunotherapy efficacy.
Rodriguez JE, Naigeon M, Goldschmidt V, Roulleaux Dugage M, Seknazi L, Danlos FX, Champiat S, Marabelle A, Michot JM, Massard C, Besse B, Ferrara R, Chaput N, Baldini C. Rodriguez JE, et al. Among authors: naigeon m. Expert Rev Anticancer Ther. 2022 Sep;22(9):915-926. doi: 10.1080/14737140.2022.2098718. Epub 2022 Jul 14. Expert Rev Anticancer Ther. 2022. PMID: 35815381 Review.
Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study.
Carril-Ajuria L, Desnoyer A, Meylan M, Dalban C, Naigeon M, Cassard L, Vano Y, Rioux-Leclercq N, Chouaib S, Beuselinck B, Chabaud S, Barros-Monteiro J, Bougoüin A, Lacroix G, Colina-Moreno I, Tantot F, Boselli L, De Oliveira C, Fridman WH, Escudier B, Sautes-Fridman C, Albiges L, Chaput-Gras N. Carril-Ajuria L, et al. Among authors: naigeon m. J Immunother Cancer. 2022 May;10(5):e004885. doi: 10.1136/jitc-2022-004885. J Immunother Cancer. 2022. PMID: 35640928 Free PMC article. Clinical Trial.
CD8+PD-1+ to CD4+PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers.
Duchemann B, Naigeon M, Auclin E, Ferrara R, Cassard L, Jouniaux JM, Boselli L, Grivel J, Desnoyer A, Danlos FX, Mezquita L, Caramella C, Marabelle A, Besse B, Chaput N. Duchemann B, et al. Among authors: naigeon m. J Immunother Cancer. 2022 Feb;10(2):e004012. doi: 10.1136/jitc-2021-004012. J Immunother Cancer. 2022. PMID: 35131864 Free PMC article.
Adoptive cell therapies in thoracic malignancies.
Lasvergnas J, Naigeon M, Chouahnia K, Zelek L, Chaput N, Duchemann B. Lasvergnas J, et al. Among authors: naigeon m. Cancer Immunol Immunother. 2022 Sep;71(9):2077-2098. doi: 10.1007/s00262-022-03142-3. Epub 2022 Feb 7. Cancer Immunol Immunother. 2022. PMID: 35129636 Free PMC article. Review.
Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial.
Riudavets M, Naigeon M, Texier M, Dorta M, Barlesi F, Mazieres J, Varga A, Cassard L, Boselli L, Grivel J, NgoCamus M, Lacroix L, Mezquita L, Besse B, Chaput N, Planchard D. Riudavets M, et al. Among authors: naigeon m. Lung Cancer. 2022 Apr;166:255-264. doi: 10.1016/j.lungcan.2021.11.018. Epub 2021 Dec 3. Lung Cancer. 2022. PMID: 34953624 Clinical Trial.
16 results